Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -5.00 -0.78% 635.00 620.00 650.00 635.00 635.00 635.00 10,563 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.4 -1.0 - 377

Renalytix Ai Share Discussion Threads

Showing 251 to 275 of 625 messages
Chat Pages: Latest  13  12  11  10  9  8  7  6  5  4  3  2  Older
DateSubjectAuthorDiscuss
19/6/2020
11:01
Same here, although in fairness you have to really know a business inside out to have the confidence to buy on a drop like that. If I'd held RENX shares since the IPO and been aware of the progress & potential then yes I'd have bought big at £1.70! Either way I still think the £4-5 zone represents a great entry point given the short, medium & long term potential.
74tom
19/6/2020
10:34
Agreed re knowing about this in March :) One of my takeaways from this year's drop is keeping a wider and more up to date watch list. I had gone all cash in mid feb and had confidence to take a couple of positions at the March lows. Can't complain but would have been great to have filled my boots completely!
homebrewruss
19/6/2020
10:04
no worries - I really like this as a long term play because end markets are so massive and as it reduces healthcare costs and adds clarity to patient pathways it could become a really significant company. There isn't yet any competition that I can find...but according to my spreadsheet renx only need c.4% of the American market to make several times your money here, so I am relaxed about that at the moment. There is also very solid insider ownership including from Mount Sinai, hardly any PI interest and I haven't read about it in any tip sheets etc. I invested 10% of my money here at an average of 3.80, and if they keep hitting milestones plan to hold indefinitely as I have not seen such potential upside for a long time (having said that I do look forward to seeing revenue start to prove the whole system is working!) - I just wish I read about it in march during the crash as opposed to in the recovery stage.
nimbo1
19/6/2020
09:54
nimbo, thanks for mentioning this on the SHA thread, I took a position after your most recent mention. re NASDAQ listing timeframe, GAN would be a good benchmark.
homebrewruss
19/6/2020
09:16
they applied for nasdaq listing on May 18th. From google 'how long does it take to process nasdaq listing?' 4-6 weeks It generally takes 4-6 weeks to process a listing application. This time frame is variable and may be shortened considerably, if the application raises no issues and the company responds to staff comments. Week 1. Company submits application for listing and NASDAQ listing Qualifications staff begins its review. So I reckon we'll hear c. end of June assuming their operations are as normal.
nimbo1
18/6/2020
15:39
Yep, if they are the first to gain FDA EUA for this type of test then they will benefit from a significant first mover advantage - especially with the Bio-Techne distribution lined up. Hopefully we'll get an update on either FractalDX or NASDAQ listing soon to keep the ball rolling on those...
74tom
18/6/2020
11:38
Thanks for the information - I'm looking forward to more colour from the company ref what this relationship means for them financially...they probably don't know completely yet.
nimbo1
18/6/2020
10:34
My interpretation (bearing in mind I am no expert) is that the test, if approved, will have a larger addressable market e.g. diagnostics (qualitative) and to support vaccine development, and to help evaluate emerging immunotherapies (quantitative). What I am now not quite sure about (given the separate EUA's), is whether there will be just the one test or two separate tests.
wan
18/6/2020
10:01
Great update - It would be the first FDA approved quantitative antibody test...and the worldwide distribution capabilities of Bio-Techne would make it a game changer with global reach...
74tom
18/6/2020
08:21
Update re Kantaros' serologic test for COVID-19 - New York, NY (June 17, 2020) Mount Sinai Health System has submitted a request to the U.S. Food and Drug Administration (FDA) for issuance of an Emergency Use Authorization (EUA) for quantitative use of its serologic test. If authorized for quantitative use, the assay could be used to provide a numeric result for the concentration of neutralizing anti-COVID-19 antibodies in plasma. In April 2020, Mount Sinai Laboratory Center for Clinical Laboratories received FDA EUA for qualitative use of the assay, an enzyme-linked immunosorbent assay or ELISA, that has now been tested on over 40,000 patients and has been a critical component of the hospital’s convalescent plasma program for emergency therapy, and testing of healthcare workers as well as the public. In a comparison of EUA tests published by the FDA (link), the EUA-authorized qualitative test had a PPV of 100%, and an NPV of 99.6%. Since then, Mount Sinai’s internationally recognized team of virologists and pathologists, including Florian Krammer, PhD, Professor of Microbiology at the Icahn School of Medicine at Mount Sinai, Carlos Cordon-Cardo, MD, PhD, Irene Heinz Given and John LaPorte Given Professor and Chair of Pathology, Molecular and Cell-Based Medicine at Mount Sinai, and Adolfo Firpo-Betancourt, MD, Professor of Pathology, Molecular and Cell Based Medicine at Mount Sinai, have been working intensely to provide new findings and data to support what they hope will be FDA authorized quantitative use of the assay. The serological assay developed by Dr. Krammer and colleagues for the screening and identification of individuals that have seroconverted was described in a paper published in Nature Medicine on May 12, 2020. Mount Sinai is hopeful that the FDA will be reviewing this request in the next few weeks. If FDA EUA is issued, Kantaro Biosciences, a Mount Sinai diagnostics venture, will also apply for FDA EUA for a commercial kit based on the Mount Sinai assay. If Kantaro’s EUA is issued, Kantaro and Bio-Techne, a leading life science tools and clinical diagnostics company, expect to provide interested laboratories access to these kits in July. Full release - hTTps://www.mountsinai.org/about/newsroom/2020/mount-sinai-seeks-eua-from-food-and-drug-administration-for-potential-quantitative-serologic-test-for-covid19-pr
wan
17/6/2020
12:54
Full quote below, there was always a lot to do...but no indication they aren’t on track "We are extremely excited to partner with Kantaro and Mount Sinai to launch what we believe will be a gold standard serology test for COVID-19," said Chuck Kummeth, President and Chief Executive Officer of Bio-Techne. "The Bio-Techne, Mount Sinai and Kantaro teams are working around the clock to develop this test, and we are on track to achieve in approximately eight weeks what would typically take 18 months or more. As the world leader in ELISA assays, Bio-Techne has substantial capacity and the ability to scale production levels to support much of our nation's needs. We look forward to providing the world with critical information related to past exposure to the virus." httpS://www.nasdaq.com/press-release/bio-techne-and-kantaro-biosciences-announce-partnership-to-develop-and-scale
74tom
17/6/2020
11:59
74tom...Thanks. To be clear, Mount Sinai was issued an Emergency Use Authorization (EUA) from the FDA for clinical testing in its CLIA certified laboratory on April 15th. Kantaro plans to seek EUA for the test kit, based on the Mount Sinai test and following final validation based on the scaled up version. Kantaro were leading regulatory processes with the intention of submitting the scaled assay for FDA EUA review in May. So, we still need obtain FDA EUA and there was quite a lot to achieve, in terms of final development and scale-up, to stay on the indicated schedule.
wan
17/6/2020
11:31
To add to the above; - It's already received FDA EUA approval and has been used in more than 30,000 tests - RENX CEO James McCullough's former company Exosome Diagnostics were acquired by Bio-techne in mid 2018, so there is a personal connection at play here by the looks of things. - The potential for global reach is real, but access to the US market is pretty much guaranteed, and that is something most companies would love to have You have to wonder what else will emerge from the RENX, Mount Sinai & Joslin Diabetes Centre partnerships in the future...
74tom
17/6/2020
11:03
I believe there are suite of important aspects that appear to set the Kantaro COVID-19 serology test apart. ELISA The ‘gold standard’ laboratory technique for serological testing, is called ELISA. The Kantaro test kit, is an enzyme-linked immunosorbent assay (ELISA) based on the Mount Sinai-developed COVID-19 serology test. As the world leader in ELISA assays, Kantaro's partner, Bio-Techne, has all the necessary credentials - Bio-Techne is a fully integrated, world leading ELISA developer and manufacturer. Accuracy - Mount Sinai Hospital Clinical Laboratory COVID-19 ELISA Antibody Test" was reported to show a Positive Predictive Value (the probability of disease if the test is positive) of 100% and a Negative Predictive Value (the probability of no disease if the test is negative) of 99.6%. Bio-Techne and Kantaro are in the process of validating the scaled assay and expect the data to confirm similar results. Availability As the world leader in ELISA assays, Bio-Techne has substantial capacity and the ability to scale production on a global scale. Ease of use A test that any medical professional can perform, hopefully, with the equipment they already own or can purchase easily, without long-term contracts and other encumbrances. In this regard, the Kantaro test kit will use a simple patient blood draw and is designed to be easily run by any laboratory in the world without costly proprietary equipment. The technology underlying the diagnostic test was created by internationally recognized virology and pathology teams from the Icahn School of Medicine at Mount Sinai.
wan
17/6/2020
09:06
Nice work as always. Yes I've been keeping an eye on the Kantoro site, I noticed last week that the availability line was changed from 'will be available soon' to 'planned for July 2020', so all appears on track...
74tom
17/6/2020
08:35
Seeing as we are fast approaching the planned availability of commercial COVID-19 test kits for clinical laboratories, which is scheduled for July 2020. I have updated the header regarding the Mount Sinai and Renalytix AI, Inc joint venture, Kantaro Biosciences. And also included a link to Kantaro's website, which is worth visiting - hTTps://kantarobio.com/
wan
16/6/2020
19:26
It’s nice to see some decent volume
nimbo1
16/6/2020
16:48
Didn't quite make it all the way back - closing bid / ask was 5.09 - 5.15 Strong after yesterday's jump, and pretty decent volume versus average totalling about £700k. Onwards and upwards!
74tom
16/6/2020
10:57
you could be right - bought a few more but they'd rather take sells than buys here
nimbo1
16/6/2020
10:50
Any consolidating will be offset by new buyers in my opinion - particularly in the US. My betting is the drop we’ve seen this morning reverses from 2pm onwards - currently I think the market markers are collecting shares to fill big delayed buys from yesterday afternoon. Nothing larger than 2.5k was declared post 4pm yet the price rose over 10% Anyway, all water under the bridge. Agree on the 3-5 year hold - just look at the growth of CareDX over the last 2 years...
74tom
16/6/2020
10:06
yes it all seems very promising. I have a 3.8 average and plan to hold for 3-5 years assuming everything goes as planned. Balancing that though we are waiting for first revenues etc and of course price will need to consolidate a bit!
nimbo1
16/6/2020
08:19
Agree Nimbo, timing the Nasdaq IPO with their first revenues was clearly the plan, and that will whet the appetite of many US investors I’d imagine, especially those aware of the macro factors. They’ve created a perfect storm as far as share price appreciation is concerned; - Existing holders have the FractalDX dividend in specie to look forward to, why would you sell when you’ll get a substantial number of free shares? - Nasdaq IPO - another exciting near term event, as we have seen with GAN this can result in a large value uplift in cases where a quality company has been relatively under the radar due to AIM liquidity. - Covid-19 involvement via Kantaro JV, this also has significant potential given the Antibody test has already received FDA EUA & has the second most accurate sensitivity / specificity of any test I’ve seen. What’s more the worldwide distribution via Bio-Techne is nailed down, so a July launch is very much on track. Expect to hear confirmation of this in the next week. Then we have the seamless underlying progress of KidneyIntelX™ described so well by Wan. Quite simply, if you sold here where else can you replicate this unique set of circumstances?
74tom
15/6/2020
22:17
My own expectations (potential £2bil + market cap in 3 years). After the recent move its a £300 mil market cap. I think over the next few months we'll see the true extent of potential - if this really is a huge improvement vs previous healthcare pathways for kidney disease I'd expect this company to be worth $1 bil+ soon after listing on nasdaq, perhaps in 6 months time. They'll be more deals with healthcare providers and insurers etc. Not to mention fda approval and eventually full Medicare coverage.
nimbo1
15/6/2020
16:50
Wan thanks. And, to put the stats another way, the US is one unhealthy country.
faz
15/6/2020
16:41
Thanks for the new thread Wan.
longshanks
Chat Pages: Latest  13  12  11  10  9  8  7  6  5  4  3  2  Older
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200810 12:48:02